NASDAQ · IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES · MID CAP
Myriad Genetics, Inc. MYGN
18 fiscal years on record · USD · FY2025 reported
SEC FILINGS ONLY
Revenue · FY2025
$824.5M
▼ 1.6% vs FY2024
EPS · FY25
$-3.95
Dividend / sh · FY25
—
Payout · FY25
—
ROE · FY25
-68.5%
Net margin · FY25
-44.4%
Dividend coverage
—
Advertisement
AdSense · Leaderboard 728×90320×100
Result
USD 824.5M
Revenue, FY2025 · full 18-year series below
Revenue
Net income
The company lost 44 cents on every revenue dollar this year.
Per share
USD -3.95
Diluted EPS, FY2025
EPS
The company pays no cash dividend.
Profitability
-68.5%
Return on equity, FY2025
ROE
Operating margin-47.0%
Net margin-44.4%
Return on assets-42.2%
Each USD of equity lost 68 cents this year.
Returned to shareholders
—
returned in FY2025 · dividends + net buybacks
Dividends paid—
Net buybacks—
Share of profit—
Consecutive raises—
Growth
+8.2% a year
revenue, compounded over five years
CAGR
3 yrs
5 yrs
10 yrs
15 yrs
Revenue
+6.7%
+8.2%
+1.1%
+4.9%
Compound annual rates per period — left blank where the series crosses a loss.
Share base
0.09B
Shares outstanding, FY2025
Change, 5 years+24.0%
Change, 10 years+35.3%
The share count grew 24% in five years — the same company, cut into more, smaller slices.
Advertisement
AdSense · Leaderboard 728×90300×250
Balance sheet
USD 706.6M
total assets, end of FY2025
Total assetsUSD 706.6M
EquityUSD 368.0M
CashUSD 149.6M
Gross debtUSD 119.9M
Net debtUSD -29.7M
Current ratio2.49×
The company holds more cash than debt.
History
18 fiscal years
Every figure from documents filed with the SEC · USD
Metric
2025
2024
2023
2022
2021
2020
2019
2018
2017
2016
2015
2014
2013
2012
2011
2010
2009
2008
Revenue $B
0.8
0.8
0.8
0.7
0.7
0.6
0.6
0.9
0.7
0.7
0.7
0.7
0.8
0.6
0.5
0.4
0.4
0.3
Operating income $B
−0.4
−0.1
−0.3
−0.1
−0.2
−0.3
−0.2
0.0
0.1
0.0
0.2
0.1
0.3
0.2
0.2
0.2
0.1
0.1
EBITDA $B
−0.4
−0.1
−0.2
−0.1
−0.2
·
−0.2
0.0
0.1
0.1
0.2
0.1
0.3
0.2
0.2
0.2
0.1
0.1
Income tax $B
−0.0
0.0
0.0
−0.0
−0.0
−0.1
−0.0
−0.0
−0.0
0.0
0.0
0.1
0.1
0.1
0.1
0.1
−0.0
0.0
Net income $B
−0.4
−0.1
−0.3
−0.1
−0.0
−0.2
−0.2
0.0
0.1
0.0
0.1
0.1
0.2
0.1
0.1
0.1
0.2
0.1
EPS, diluted $
−3.95
−1.41
−3.18
−1.39
−0.35
−2.99
−2.69
0.06
1.85
0.25
1.60
1.07
2.25
1.77
1.30
1.10
1.54
0.86
Dividend / sh $
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
Payout %
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
·
ROE %
−68.5
−17.2
−31.6
−12.1
−2.9
−24.9
−19.9
0.4
15.4
2.3
16.7
11.6
24.3
21.6
18.7
17.9
30.7
19.7
Shares out B
0.09
0.09
0.09
0.08
0.08
0.08
0.07
0.07
0.07
0.07
0.07
0.07
0.07
0.08
0.08
0.09
0.09
·
Slide the table for earlier years · "·" marks figures not disclosed in the filing for that year.
How we verifyAUDITED
56 of 56
checks passed before publication
EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidity
Every figure was compared against the original statement: 0 failures and 0 presentation gaps.
What we don’t show
We’d rather say what’s missing than fill the gap with an estimate.
P/E rationeeds a market quote — not yet licensed
Market capitalizationneeds a market quote — not yet licensed
Dividend yieldneeds a market quote — not yet licensed
Price-to-bookneeds a market quote — not yet licensed